Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 7Carcinoma, Hepatocellular 4Rectal Neoplasms 2Stomach Neoplasms 1Peripheral Nervous System Diseases 1Neoplasm Metastasis 1Liver Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Nivolumab 3Ramucirumab 2Radiotherapy 2Paclitaxel 2Cisplatin 2Capecitabine 2tucatinib 1Trastuzumab 1Taxes 1Specimen Handling 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Folfox protocol 1Fluorouracil 1Drug Therapy 1Cetuximab 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Adenocarcinoma Of Esophagus × Folfox protocol × Clear all
NCT07221149 2026-06-04

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Bristol-Myers Squibb

Phase 2/3 Recruiting
690 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡